S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:LNTH

Lantheus - LNTH Stock Forecast, Price & News

$58.64
+1.14 (+1.98%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$56.86
$59.11
50-Day Range
$47.76
$62.08
52-Week Range
$25.49
$87.47
Volume
1.02 million shs
Average Volume
909,755 shs
Market Capitalization
$4.04 billion
P/E Ratio
39.36
Dividend Yield
N/A
Price Target
$102.80

Lantheus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
75.3% Upside
$102.80 Price Target
Short Interest
Healthy
5.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.72mentions of Lantheus in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.11 M Sold Last Quarter
Proj. Earnings Growth
11.05%
From $3.53 to $3.92 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

42nd out of 1,053 stocks

Diagnostic Substances Industry

1st out of 17 stocks


LNTH stock logo

About Lantheus (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Company Calendar

Last Earnings
11/03/2022
Today
2/01/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
Employees
612
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$102.80
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$91.00
Forecasted Upside/Downside
+75.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-71,280,000.00
Pretax Margin
20.21%

Debt

Sales & Book Value

Annual Sales
$425.21 million
Cash Flow
$1.33 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
67,731,000
Market Cap
$4.04 billion
Optionable
Optionable
Beta
0.78

Key Executives

  • Mary Anne HeinoMary Anne Heino
    President, Chief Executive Officer & Director
  • Paul BlanchfieldPaul Blanchfield
    Chief Operating Officer
  • Robert J. MarshallRobert J. Marshall
    Chief Financial Officer & Treasurer
  • Simon Robinson
    Senior VP-Research & Pharmaceutical Development
  • Iryna Teslenko
    Vice President-Clinical Development













LNTH Stock - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price forecast for 2023?

5 analysts have issued 1 year price objectives for Lantheus' stock. Their LNTH share price forecasts range from $91.00 to $120.00. On average, they anticipate the company's share price to reach $102.80 in the next year. This suggests a possible upside of 75.3% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2023?

Lantheus' stock was trading at $50.96 on January 1st, 2023. Since then, LNTH shares have increased by 15.1% and is now trading at $58.64.
View the best growth stocks for 2023 here
.

Are investors shorting Lantheus?

Lantheus saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 3,450,000 shares, a decrease of 5.5% from the December 31st total of 3,650,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is presently 3.1 days. Approximately 5.1% of the shares of the company are sold short.
View Lantheus' Short Interest
.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our LNTH earnings forecast
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, November, 4th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. The medical equipment provider had revenue of $102.10 million for the quarter, compared to analysts' expectations of $97.13 million. Lantheus had a net margin of 13.35% and a trailing twelve-month return on equity of 37.77%. The business's quarterly revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.04 earnings per share.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of $0.95-$0.98 for the period, compared to the consensus EPS estimate of $0.86. The company issued revenue guidance of $243.00 million-$247.00 million, compared to the consensus revenue estimate of $238.01 million.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Reinhart Partners Inc. (0.84%), Congress Asset Management Co. MA (0.50%), Allspring Global Investments Holdings LLC (0.45%), Assenagon Asset Management S.A. (0.45%), Peregrine Capital Management LLC (0.39%) and New York State Teachers Retirement System (0.33%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends
.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $58.64.

How much money does Lantheus make?

Lantheus (NASDAQ:LNTH) has a market capitalization of $4.04 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71,280,000.00 in net income (profit) each year or $1.49 on an earnings per share basis.

How many employees does Lantheus have?

The company employs 612 workers across the globe.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.

This page (NASDAQ:LNTH) was last updated on 2/2/2023 by MarketBeat.com Staff